Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study

Stefan Fruehauf, Burkhard Otremba, Oliver Stötzer, Christine Rudolph, Stefan Fruehauf, Burkhard Otremba, Oliver Stötzer, Christine Rudolph

Abstract

Introduction: Febrile neutropenia (FN) is a serious and frequent complication of cytotoxic chemotherapy. Biosimilar filgrastim (Nivestim™, Hospira Inc, A Pfizer Company, Lake Forest, IL, USA) is a granulocyte-colony stimulating factor licensed for the treatment of neutropenia and FN induced by myelosuppressive chemotherapy. The primary goal of this VENICE study (ClinicalTrials.gov identifier, NCT01627990) was to observe the tolerability, safety and efficacy of biosimilar filgrastim in patients receiving cancer chemotherapy.

Methods: This was a prospective, multicenter, non-interventional, longitudinal study. Consenting adult patients with solid tumors or hematologic malignancies for whom cytotoxic chemotherapy and treatment with biosimilar filgrastim was planned were enrolled.

Results: Among the enrolled patients (N = 386), 81% were female, with a median age (range) of 61 (22-92) years, with 39% >65 years old. Most patients (n = 338; 88%) had solid tumors and the remainder (n = 49; 13%) had hematological malignancies. The majority of the patients (64%) received biosimilar filgrastim as primary prophylaxis and 36% as secondary prophylaxis. At the follow-up visits, for the majority of patients (95.6%) there had been no change in chemotherapy dose due to FN. For two patients (0.5%) the chemotherapy was discontinued due to FN and for four patients (1.0%) the chemotherapy dose was reduced due to FN. For the majority of patients (96.9%) the chemotherapy cycle following the first biosimilar filgrastim treatment was not delayed due to FN. For 3 patients (0.8%), the chemotherapy was delayed following the first biosimilar filgrastim treatment. Less than one-third (29.8%) of the patients experienced ≥1 adverse event that was at least potentially related to biosimilar filgrastim treatment.

Conclusions: Biosimilar filgrastim was effective and well-tolerated in both the primary and secondary prophylactic setting in patients undergoing chemotherapy for solid tumors and hematological malignancies.

Trial registration: ClinicalTrials.gov identifier, NCT01627990.

Funding: Hospira Inc, A Pfizer Company, Lake Forest, IL, USA.

Keywords: Biosimilar; Chemotherapy; Filgrastim; Granulocyte-colony stimulating factor; Hematology; Neutropenia; Nivestim; Oncology.

References

    1. Villafuerte-Gutierrez P, Villalon L, Losa JE, Henriquez-Camacho C. Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update. Adv Hematol. 2014;986938.
    1. Fontanella C, Bolzonello S, Lederer B, Aprile G. Management of breast cancer patients with chemotherapy-induced neutropenia or febrile neutropenia. Breast Care (Basel). 2014;9:239–245. doi: 10.1159/000366466.
    1. Wang XJ, Lopez SE, Chan A. Economic burden of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review. Crit Rev Oncol Hematol. 2015;94:201–212. doi: 10.1016/j.critrevonc.2014.12.011.
    1. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325:164–170. doi: 10.1056/NEJM199107183250305.
    1. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer. 1993;29A:319–324. doi: 10.1016/0959-8049(93)90376-Q.
    1. Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma: a randomized controlled trial. Blood. 1992;80:1430–1436.
    1. Ribeiro D, Veldwijk MR, Benner A, et al. Differences in functional activity and antigen expression of granulocytes primed in vivo with filgrastim, lenograstim, or pegfilgrastim. Transfusion. 2007;47(6):969–980. doi: 10.1111/j.1537-2995.2007.01241.x.
    1. Mhaskar R, Clark OA, Lyman G, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev. 2014;10:CD003039.
    1. Nahon S, Mansour R, Meher B, Soumoudronga R, Gasnereau I, Labourey JL. Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study. Support Care Cancer. 2015
    1. Gascon P. Presently available biosimilars in hematology-oncology: G-CSF. Target Oncol. 2012;7(Suppl 1):S29–S34. doi: 10.1007/s11523-011-0190-9.
    1. European Medicines Agency. NivestimTM/filgrastim. EPAR Product Information. (05/01/2015 Nivestim -EMEA/H/C/001142 -N/0027). Available: Date accessed 9/27/2016.
    1. Kamioner D, Fruehauf S, Maloisel F, Cals L, Lepretre S, Berthou C. Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia. BMC Cancer. 2013;13:547. doi: 10.1186/1471-2407-13-547.
    1. Crawford J, Caserta C, Roila F, on behalf of the ESMO Guidelines Working Group. Clinical practice guidelines. Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol 2010;21:(Supplement 5):248–251.
    1. Crawford J, Dale DC, Kuderer NM, et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw. 2008;6:109–118.
    1. Timmer-Bonte JN, de Boo TM, Smit HJ, et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol. 2005;23:7974–7984. doi: 10.1200/JCO.2004.00.7955.
    1. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23:1178–1184. doi: 10.1200/JCO.2005.09.102.
    1. Wolff D, Culakova E, Poniewierski MS, Lyman GH, Dale DC, Crawford J. Predictors of chemotherapy-induced neutropenia and its complications: results from a prospective nationwide registry. J Support Oncol. 2005;3:24–25.
    1. Cameron D. Management of chemotherapy-associated febrile neutropenia. Br J Cancer. 2009;101(Suppl 1):S18–S22. doi: 10.1038/sj.bjc.6605272.
    1. Hughes WT, Armstrong D, Bodey GP, et al. Support Care Cancer 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730–751. doi: 10.1086/339215.
    1. Krell D, Jones AL. Impact of effective prevention and management of febrile neutropenia. Br J Cancer. 2009;101(Suppl 1):S23–S26. doi: 10.1038/sj.bjc.6605273.
    1. Padilla G, Ropka ME. Quality of life and chemotherapy induced neutropenia. Cancer Nurs 28:167–171 11.
    1. Wagner LI, Beaumont JL, Ding B, et al. Measuring health-related quality of life and neutropenia-specific concerns among older adults undergoing chemotherapy: validation of the Functional Assessment of Cancer Therapy-Neutropenia (FACT-N) Support Care Cancer. 2008;16(1):47–56. doi: 10.1007/s00520-007-0270-7.
    1. Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42:2433–2453. doi: 10.1016/j.ejca.2006.05.002.
    1. Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8–32. doi: 10.1016/j.ejca.2010.10.013.
    1. Lyman GH, Kuderer NM. Prevention and treatment of venous thromboembolism among patients with cancer: the American Society of Clinical Oncology Guidelines. Thromb Res. 2002;125(Suppl 2):S120–S127.
    1. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. NCCN Clinical Practice Guidelines in Oncology. Myeloid Growth Factors. Version 2.2014. . J Clin Oncol. 2006;24:3187–3205. doi: 10.1200/JCO.2006.06.4451.
    1. Waller CF, Bronchud M, Mair S, Challand R. Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial. Ann Hematol. 2010;89:971–978. doi: 10.1007/s00277-010-0973-6.
    1. Waller CF, Bronchud M, Mair S, Challand R. Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial. Ann Hematol. 2010;89:927–933. doi: 10.1007/s00277-010-0961-x.
    1. Skrlin A, Radic I, Vuletic M, et al. Comparison of the physicochemical properties of a biosimilar filgrastim with those of reference filgrastim. Biologicals. 2010;38:557–566. doi: 10.1016/j.biologicals.2010.05.002.
    1. Waller CF, Semiglazov VF, Tjulandin S, Bentsion D, Chan S, Challand R. A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer. Onkologie. 2010;33:504–511. doi: 10.1159/000319693.
    1. Brito M, Esteves S, André R, Isidoro M, Moreira A. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study. Support Care Cancer. 2016;24(2):597–603. doi: 10.1007/s00520-015-2818-2.
    1. Abraham I, Tharmarajah S, MacDonald K. Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors. Expert Opin Drug Saf. 2013;12:235–246. doi: 10.1517/14740338.2013.770472.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren